We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stakeholders Seek Clarification of RMAT Eligibility Criteria
Stakeholders Seek Clarification of RMAT Eligibility Criteria
Biocom and Gilead Sciences asked the FDA for clarification on eligibility criteria for its Regenerative Medicine Advanced Therapy designation in comments on the agency’s draft guidance, while industry trade groups requested more data on the success of the program.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor